GSK3B and familial pancreatic carcinoma: Inhibition of GSK-3β activity by AR-A014418 or by a dominant negative form of GSK-3β represses its nuclear accumulation via proteasomal degradation and arrests pancreatic tumour growth in vivo and decreases NF-κB-mediated pancreatic cancer cell survival and proliferation in established tumour xenografts [22].